摘要
2017年美国风湿病学会发布的最新防治糖皮质激素性骨质疏松(GIOP)的指南中首次将地诺单抗(Denosumab)作为GIOP的治疗药物。地诺单抗基于OPG/RANKL/RANK信号通路,特异性地将骨骼系统与免疫系统相结合,是骨免疫学治疗的新靶点。其通过与特异性靶向核因子κB受体活化因子配体(RANKL)结合,抑制破骨细胞的活化和发展,从而减少骨吸收,增加骨密度。本文介绍了GIOP的形成机制和地诺单抗的作用机制,并根据报道的Ⅳ期临床研究以及细胞和动物实验数据,探讨地诺单抗的治疗特点及地诺单抗在治疗GIOP中的应用前景和存在的问题。
Denosumab was first approved to be used as a treatment for glucocorticoid-induced osteoporosis(GIOP)in the latest guidelines for the prevention and treatment of GIOP released by the American College of Rheumatology in 2017.Denosumab,based on OPG/RANKL/RANK signaling pathway,specifically binds the skeletal system to the immune system and is a new target for bone immunological therapy.It inhibits osteoclast activation and development by binding to receptor activator of NF-kB ligand(RANKL),thereby reducing bone resorption and increasing bone mineral density.In this paper,the formation mechanism of GIOP and the mechanism of action of denosumab are introduced,and the therapeutic characteristics of denosumab,application prospect and existing problems of denosumab in the treatment of GIOP are discussed based on the reported phase IV clinical trial and cell and animal experimental data.
作者
杨超富
谭国庆
徐展望
Yang Chaofu;Tan Guoqing;Xu Zhanwang(Shandong University of Traditional Chinese Medicine,Jinan 250039,China;Department of Spinal Orthopedics,Affiliated Hospital of Shandong University of Traditional Chinese Medicine,Jinan 250013,China)
出处
《实用药物与临床》
CAS
2023年第10期951-956,共6页
Practical Pharmacy and Clinical Remedies
基金
山东省自然科学基金面上项目(ZR2020MH362)
全国名老中医专家传承工作室建设项目(国中医药人教函[2022]75号)。
关键词
地诺单抗
糖皮质激素性骨质疏松
联合用药
Denosumab
Glucocorticoid-induced osteoporosis(GIOP)
Combined medication
